0001246360-13-000516.txt : 20130118 0001246360-13-000516.hdr.sgml : 20130118 20130118170012 ACCESSION NUMBER: 0001246360-13-000516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130116 FILED AS OF DATE: 20130118 DATE AS OF CHANGE: 20130118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quinn Anthony CENTRAL INDEX KEY: 0001532219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23155 FILM NUMBER: 13538156 MAIL ADDRESS: STREET 1: 128 SPRING STREET, SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNAGEVA BIOPHARMA CORP CENTRAL INDEX KEY: 0000911326 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 561808663 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: (781) 357-9900 MAIL ADDRESS: STREET 1: 128 SPRING STREET STREET 2: SUITE 520 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: TRIMERIS INC DATE OF NAME CHANGE: 19970516 4 1 form.xml PRIMARY DOCUMENT X0306 4 2013-01-16 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532219 Quinn Anthony 128 SPRING STREET, SUITE 520 LEXINGTON MA 02421 false true false false SVP, Chief Medical Officer Common Stock 2013-01-16 4 M false 353 0.95 A 20388 D Common Stock 2013-01-16 4 S false 5353 50.07 D 15035 D Common Stock 2013-01-17 4 M false 200 0.95 A 15235 D Common Stock 2013-01-17 4 S false 200 50 D 15035 D Stock Option (Right to Buy) 0.95 2013-01-16 4 M false 353 0 D 2019-10-07 Common Stock 353 48611 D Stock Option (Right to Buy) 0.95 2013-01-17 4 M false 200 0 D 2019-10-07 Common Stock 200 48411 D The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 16, 2012. The Stock Option granted the reporting person an option to purchase 101,080 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 08/31/2010, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $50.00 to $50.22. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. /s/ Anthony Quinn 2013-01-18